Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harpagophytum procumbens versus topical hydrocortisone for genital skin inflammation in candidal vulvovaginitis
IRCT20210508051222N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of hydrocortisone, clotrimazole, diiodohydroxyquinoline and aloe vera gel in vulvovaginal candidiasis (VVC) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Burning of the genitalia, Itching of the genitalia and 2 more. Started Jul 2021; status: completed.
02
Drugs
hydrocortisoneclotrimazolediiodohydroxyquinolinealoe vera gel
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on IRCT20210508051222N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210508051222N1.